Margaretha L M Prins

Margaretha L M Prins

Auto-generated profile, based on publicly available information

Margaretha L M Prins

Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MPManon L. M. Prins
Manon L. M. Prins
GRGeert Roozen
Geert Roozen
CPCilia. R. Pothast
Cilia. R. Pothast
WHWesley Huisman
Wesley Huisman
RBRob van Binnendijk
Rob van Binnendijk
ARAnna H. E. Roukens
Anna H. E. Roukens
Fractional dosing can be a cost-effective vaccination strategy to accelerate individual and herd immunity in a pandemic. We assessed the immunogenicity and safety of primary intradermal (ID) vaccination, with a 1/5th dose compared with the standard intramuscular (IM) dose of mRNA-1273 in SARS-CoV-2 naïve persons. We conducted an open-label, non-inferiority, randomized controlled trial in the Netherlands between June and December 2021. One hundred and fifty healthy and SARS-CoV-2 naïve participants, aged 18–30 years, were randomized (1:1:1) to receive either two doses of 20 µg mRNA-1273 ID with a standard needle (SN) or the Bella-mu® needle (BM), or two doses of 100 µg IM, 28 days apart. The primary outcome was non-inferiority in seroconversion rates at day 43 (D43), defined as a neutralizing antibody concentration threshold of 465 IU/mL, the lowest response in the IM group. The non-inferiority margin was set at −15%. Neutralizing antibody concentrations at D43 were 1789 (95% CI: 1488–2150) in the IM and 1263 (951–1676) and 1295 (1020–1645) in the ID-SN and ID-BM groups, respectively. The absolute difference in seroconversion proportion between fractional and standard-dose groups was −13.95% (−24.31 to −3.60) for the ID-SN and −13.04% (−22.78 to −3.31) for the ID-BM group and exceeded the predefined non-inferiority margin. Although ID vaccination with 1/5th dose of mRNA-1273 did not meet the predefined non-inferior criteria, the neutralizing antibody concentrations in these groups are far above the proposed proxy for protection against severe disease (100 IU/mL), justifying this strategy in times of vaccine scarcity to accelerate mass protection against severe disease.

25 October 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
GRGeert Roozen
Geert Roozen
MPMargaretha L.M. Prins
Margaretha L.M. Prins
Robert van BinnendijkRobert van Binnendijk
Robert van Binnendijk
Gerco Den HartogGerco Den Hartog
Gerco Den Hartog
VKVincent P. Kuiper
Vincent P. Kuiper
ARAnna H.E. Roukens
Anna H.E. Roukens

21 July 2023 in Virus Research
Verified
Journal Article
Open access
MPManon L.M. Prins
Manon L.M. Prins
CPCorine Prins
Corine Prins
JVJutte J. C. De Vries
Jutte J. C. De Vries
LVLeo G. Visser
Leo G. Visser
ARAnna H.E. Roukens
Anna H.E. Roukens
Nanoporous microneedle arrays (npMNA) are being developed as skin patches for vaccine delivery. As alternative for needle-based immunisation, they may potentially result in higher vaccine acceptance, which is important for future mass vaccination campaigns to control outbreaks, such as COVID-19, and for public vaccination in general. In this study we investigated the safety and immunogenicity of needle-free intradermal delivery of a fractional third or fourth dose of mRNA-1273 vaccine by npMNA. This study was an open-label, randomised-controlled, proof-of-concept study. Healthy adults were eligible if they had received a primary immunisation series against SARS-CoV-2 with two doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) mRNA vaccine. A history of a COVID-19 infection or booster vaccination with mRNA-1273 or BNT162b2 was allowed if it occurred at least three months before inclusion. Participants were randomised in a 1:1 ratio to receive 20 µg mRNA-1273 vaccine, either through npMNA patch applied on the skin (ID-patch group), or through intramuscular (IM) injection (IM-control group). Primary outcomes were reactogenicity up to two weeks after vaccination, and fold-increase of SARS-CoV-2 spike S1-specific IgG antibodies 14 days post-vaccination. In April 2022, 20 participants were enroled. The geometric mean concentration (GMC) did not increase in the ID-patch group after vaccination, in contrast to the IM-control group (GMC was 1,006 BAU/mL (95% CI 599–1,689), 3,855 (2,800–5,306), and 3,513 (2,554–4,833) at day 1, 15 and 29, respectively). In addition, SARS-CoV-2-specific T cell responses were lower after ID vaccination through npMNA. Needle-free delivery of 20 µg mRNA-1273 vaccine by npMNA failed to induce antibody and T cell responses. As this is a potentially very useful vaccination method, it is important to determine which adjustments are needed to make this npMNA successful. NCT05315362.

12 July 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
MPMargaretha L M Prins
Margaretha L M Prins
BBBartholomeus E P B Ballieux
Bartholomeus E P B Ballieux
Onno C. MeijerOnno C. Meijer
Onno C. Meijer
APA.M. Pereira
A.M. Pereira
MNMichiel F Nijhoff
Michiel F Nijhoff
We report on a case of a 50-year-old female patient with primary hyperaldosteronism, in whom adrenal venous sampling was required to differentiate between unilateral and bilateral disease. Because of a history of severe allergy to iodinated contrast media, premedication with glucocorticoids was indicated. Exogenous glucocorticoids, however, can affect measurements of serum cortisol. To avoid this potential confounding effects on the cortisol assay, we decided to use dexamethasone instead of prednisolone or hydrocortisone. A high-dose adrenocorticotropin (ACTH) stimulation test with the simultaneous use of dexamethasone revealed an adequate adrenal cortisol response. ACTH-stimulated adrenal venous sampling showed reliable results, which provided a solid basis for further clinical decision-making.

8 November 2025 in Transplant Infectious Disease
Verified
Journal Article
Open access
MPManon L. M. Prins
Manon L. M. Prins
EDErnst D. van Dokkum
Ernst D. van Dokkum
AVAiko P. J. de Vries
Aiko P. J. de Vries
MTMaarten E. Tushuizen
Maarten E. Tushuizen
DHDanny van der Helm
Danny van der Helm
GGGeert H. Groeneveld
Geert H. Groeneveld
Background: Respiratory viral infections (RVIs) can have distinct clinical presentations and outcomes in non‐lung solid organ transplant (SOT) recipients compared to non‐transplant and lung transplant patients. Understanding their impact is crucial for improving patient care and outcomes. Methods: This multicenter retrospective study analyzed adult non‐lung SOT recipients with PCR‐confirmed symptomatic RVIs from eight Dutch hospitals (January 2013–July 2024) to characterize clinical characteristics and outcomes of mono‐ and co‐infections and identify risk factors for intensive care admission or 30‐day mortality. Results: In total, 603 RVIs were identified in 460 recipients (kidney: 501; liver: 75; pancreas/islet of Langerhans: 4; combined: 23). The most common viruses were SARS‐CoV‐2 (36%), influenza A/B (29%), rhinovirus (14%), and RSV (7%). Influenza cases showed higher rates of fever (72%), common cold symptoms (37%), and myalgia (29%) than other viruses. Hospitalization occurred in 68% (384/565). Factors independently associated with intensive care admission or 30‐day mortality included higher CURB‐65 score (OR 1.91; 95% CI 1.36–2.70; p < 0.01), radiologic infiltrates (OR 3.04; 95% CI 1.60–5.80; p < 0.01), and SARS‐CoV‐2 infection (OR 1.67; 95% CI 1.05–2.67; p = 0.03). In contrast, influenza infection was associated with a lower risk (OR 0.21; 95% CI 0.07–0.62; p < 0.01). Co‐infections were not linked to worse outcomes compared to mono‐infections. Conclusion: Overall, RVIs in non‐lung SOT recipients were associated with high hospitalization and mortality rates. SARS‐CoV‐2 posed the highest risk for complications, while influenza was associated with a lower risk of severe outcomes. No association was found between co‐infection and poor outcomes.

24 April 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
WDWillian J. van Dijk
Willian J. van Dijk
MPManon L.M. Prins
Manon L.M. Prins
ARAnna H.E. Roukens
Anna H.E. Roukens
GRGeert Roozen
Geert Roozen
MRMeta Roestenberg
Meta Roestenberg
FRFrits R. Rosendaal
Frits R. Rosendaal
Background: Fractional-dosed intradermal (i.d.) vaccination produces antibody concentrations above the proposed proxy for protection against severe disease as compared with intramuscular (i.m.) vaccination and may be associated with a decreased prothrombotic effect. Objectives: To assess changes in coagulation following standard dosed i.m. or fractional-dosed i.d. (one- fifth of i.m.) mRNA-1273 SARS-CoV-2 vaccine and to determine the association between the in flammatory response and coagulation. Methods: This study was embedded in a randomized controlled trial assessing the immunogenicity of an i.d. fractional-dosed mRNA-1273 vaccine. Healthy participants, aged 18 to 30 years, were randomized (2:1) to receive either 2 doses of i.d. or i.m. vaccine. Blood was drawn prior to first and second vaccination doses and 1 and 2 weeks after the second dose. The outcomes were changes in coagulation parameters (primary endpoint peak height of the thrombin generation curve) and in flammation (highsensitivity C-reactive protein [hs-CRP]). Results: One hundred twenty-three participants were included (81 i.d.; 42 i.m.). Peak height increased after vaccination (i.m., 28.8 nmol; 95% CI, 6.3-63.8; i.d., 17.3 nmol; 95% CI, 12.5-47.2) and recovered back to baseline within 2 weeks. I.m. vaccination showed a higher in flammatory response compared with i.d. vaccination (extra increase hs-CRP, 0.92 mg/L; 95% CI, 0.2-1.7). Change in endogenous thrombin potential was associated with change in hs-CRP (beta, 28.0; 95% CI, 7.6-48.3). Conclusion: A transient increase in coagulability after mRNA-1273 SARS-CoV-2 vaccination occurred, which was associated with the in flammatory response. While i.d. administration showed antibody concentrations above the proposed proxy for protection against severe disease, it was associated with less systemic in flammation. Hence, i.d. vaccination may be safer.